Indication
Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Instanyl 100 microgram/dosis, neusspray oplossingNetherlandsAuthorised
- Instanyl 100 microgram neusspray, oplossing in verpakking voor éénmalig gebruikNetherlandsAuthorised
- Instanyl 200 microgram/dosis, neusspray oplossingNetherlandsAuthorised
- Instanyl 200 microgram neusspray, oplossing in verpakking voor éénmalig gebruik